Methods of treating residual breast cancer with trastuzumab emtansine

MYPI2025000495A0Undetermined Publication Date: 2020-04-15GENENTECH INC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
MYPI2025000495
Authority / Receiving Office
MY · MY
Patent Type
Applications
Current Assignee / Owner
Priority Date
2018-10-15
Filing Date
2019-04-24
Publication Date
2020-04-15
Patent Text Reader

Abstract

Methods of treating patients having HER2-positive early breast cancer with the antibody-drug conjugate trastuzumab emtansine (T-DM1) are provided. Fig. 1
Need to check novelty before this filing date? Find Prior Art